Aminosin Plus Injection

Adult dosage

Adults are based on an amino acid dosage of 0.8g per kg of body weight per day (corresponding to 9.5mL of this medication). It is administered intravenously via central venous access. This medication is provided alongside glucose and other sources that can adequately supply calories through non-oral nutritional therapy.

Children's dosage

Infants are based on an amino acid dosage of 2.2g per kg of body weight per day (corresponding to 26mL of this medication). It is administered intravenously via central venous access. This medication provides calories through non-oral nutritional therapy.

This medication must be used strictly according to a physician's instructions and should not be used arbitrarily without a prescription. It should not be administered to patients with allergic reactions to its components, those with severely impaired liver function, or patients with severe kidney disease. Use should also be avoided in patients with congenital amino acid metabolism disorders or those with heart failure, pulmonary edema, or oliguria. Particular caution is needed for specific patient groups, such as those with severe dehydration or electrolyte imbalances, and for those with impaired liver or kidney function. Dosage should be adjusted based on the patient's condition. During the administration of this medication, severe side effects such as allergic reactions or anaphylaxis may occur, so careful monitoring is necessary. During non-oral nutrition therapy, blood ammonia levels may rise, necessitating regular blood tests to monitor the condition. If any abnormal symptoms occur, administration should be stopped immediately. Additionally, electrolyte concentrations, blood glucose, fluid balance, and liver and kidney function should be regularly assessed to ensure they remain normal. This medication should be administered alongside appropriate energy sources, and particularly when combined with glucose, blood sugar and urine glucose levels should be carefully monitored. In the case of overdose, issues such as increased blood volume, electrolyte imbalance, and acidosis may arise, so the infusion rate should be adjusted and stopped immediately if abnormal symptoms occur. The safety of this medication has not been fully established for pregnant or breastfeeding women, and it should only be used when the therapeutic benefits outweigh the risks. In the case of children and the elderly, special caution is needed as physiological functions may differ; particularly in infants under 2 years old, administration should be done carefully while maintaining a shaded condition. This medication is for single use only; it should be used immediately after opening and any remaining contents should be discarded. When storing, avoid direct sunlight and keep at room temperature. Do not use if the contents are discolored or cloudy, or if the packaging is damaged. Finally, maintain strict aseptic conditions while preparing and administering this medication to reduce the risk of infection.

Serious side effects

Anaphylaxis, anaphylactoid reactions, angioedema (severe swelling), severe allergic reactions, urticaria, shock, respiratory symptoms, pulmonary vascular deposition, liver abnormalities (liver failure, cirrhosis, liver fibrosis, cholestasis, hepatic steatosis), jaundice, renal impairment, severe edema, oliguria, anuria, elevated blood pressure, congestive heart failure, pulmonary edema, severe neurological symptoms (headaches, confusion, etc.)

Mild side effects

• Fever
• chills
• hypotension
• hypertension
• arthralgia
• myalgia
• urticaria
• rash
• pruritus
• erythema

This medication should be stored in a sealed container to protect it from air and moisture. A cool place between 1 and 25 degrees Celsius is suitable for storage. Take care not to place it in excessively hot or cold areas.

Appearance

A colorless or pale yellow transparent liquid in a colorless transparent glass vial.

Package unit

200 milliliters/vial, 250 milliliters/vial